Issues
-
Cover Image
Cover Image
A cancer cell's behavior heavily depends on its immediate neighbors, but it is not known how different patterns of immune and stromal cell infiltrates are set up, nor how stable they may be. A comprehensive histological look at over 100 lung cancer tumors revealed four major subtypes of tumors, based on which immune cells reside in the tumors. The worst outcomes were associated with the plasma cell subtype, which seems to be sustained by APRIL-expressing myeloid cells. Artwork by Lewis Long is based on Fig. 5H in the article by Kurebayashi and colleagues that starts on p. 234 of this issue of Cancer Immunology Research. - PDF Icon PDF LinkTable of Contents
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
Cancer Immunology Miniatures
Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma
Research Articles
Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism
PD-1 Blockade Expands Intratumoral Memory T Cells
Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors
Immunotherapy against Metastatic Melanoma with Human iPS Cell–Derived Myeloid Cell Lines Producing Type I Interferons
CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.